Director Dr. Lo William Wing Yan filed a Form 4 with the SEC on November 17, 2026, disclosing the exercise of stock options and acquisition of ordinary shares in Regencell Bioscience Holdings Ltd.

Key Highlights

  • Transaction date: November 17, 2026, the date of the earliest reported transaction.
  • Option exercise: Dr. Lo exercised a stock option (transaction code M) covering 36,001 ordinary shares at an exercise price of $0.84 per share.
  • Shares acquired: 36,001 ordinary shares, par value $0.00001, were acquired (coded A) at $0.84.
  • Resulting ownership: Following the transaction, Dr. Lo directly beneficially owned 485,629 ordinary shares.
  • Option details: The stock option had an exercisable date of January 1, 2023, and an expiration date of January 1, 2033.
  • Price adjustment noted: According to the filing, "The exercise price has given effect to the share split(s) of the Issuer since the date of grant of the option."

Director Lo's Option Exercise at Regencell Bioscience on November 17, 2026

Dr. Lo William Wing Yan, a director of Regencell Bioscience Holdings Ltd (NASDAQ:RGC), reported a change in beneficial ownership through a Form 4 filed November 17, 2026. The filing discloses a single transaction: the exercise of a stock option, reflected under transaction code M in both Table I (non-derivative securities) and Table II (derivative securities).

According to the filing, Dr. Lo acquired 36,001 ordinary shares (par value $0.00001) at a price of $0.84 per share. The underlying option, which carried the same $0.84 exercise price, had a date exercisable of January 1, 2023, and an expiration date of January 1, 2033. The filing notes that the exercise price reflects adjustments for share splits by the issuer since the original grant date. The price of the derivative security at exercise is listed as $0, and the option covered 36,001 shares.

Following the reported transaction, Dr. Lo directly held 485,629 ordinary shares, as reported in both tables of the filing. The Form 4 was signed by James Wai Hong Chung as attorney-in-fact on November 17, 2026, and was filed as an individual, single-reporting-person disclosure.

What Was Disclosed

Dr. Lo William Wing Yan, a director of Regencell Bioscience Holdings Ltd, disclosed the exercise of 36,001 stock options at $0.84 per share on November 17, 2026, resulting in direct beneficial ownership of 485,629 ordinary shares.